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Abstract : A final diagnosis of bladder cancer is made based on a pathological 
assessment using cystoscopy and biopsy.  Recently, computed tomography （CT） and 
magnetic resonance imaging （MRI） have become widely used as screening tests 
for hematuria, and there are scattered reports of new imaging modalities such as 
CT urography （CTU） and diffusion-weighted MRI being useful in the detection 
of bladder cancer.  However, there are no reports comparing CTU and MRI in 
this context.  In the present study, we compared the bladder cancer detection 
abilities of CTU and MRI.  We analyzed 58 cases of bladder cancer that had 
been examined by both CTU and bladder MRI.  The objects of comparison were 
T2-weighted images and diffusion-weighted images for MRI and contrast CT imag-
es of the renal parenchyma and excretory phases for CTU.  Bladder cancer was 
conrmed histopathologically via either biopsy or surgery for all cases.  For patients 
with multiple bladder cancer, up to three lesions per case were included in the 
analysis.  Two independent readers assessed all cases.  Out of 91 lesions from 58 
cases, Reader 1 detected 72 （79.1％） and 65 cases （71.4％）, and Reader 2 detected 
69 （75.8％） and 70 （76.9％）, using MRI and CTU, respectively. The κ -values for 
Reader 1 versus Reader 2 were 0.780 for MRI and 0.857 for CT, showing high 
diagnostic consistency.  MRI showed a higher lesion detection rate than CTU, but 
this difference was not statistically significant.  This study showed no significant 
difference in bladder cancer detection rate between CTU and MRI, conrming the 
value of MRI in the clinical diagnosis of bladder cancer.
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Introduction
　Bladder cancer is the most frequently occurring malignant tumor of the urinary tract1, 2）.  The 
most common symptom of bladder cancer is hematuria, and when hematuria is present and 
bladder cancer is clinically suspected, ultrasonography and cystoscopy are typically performed as 
screening examinations 1, 3）.  Excretory urography is another urinary tract screening method that 
has long been used, but it has become increasingly replaced by CT urography （CTU） in recent 
times 4-7）.  CTU involves thin-section imaging of the urinary tract by multidetector CT （MDCT） 
during the excretory phase after intravenous injection of an iodine contrast agent, at high spatial 
and contrast resolution.  CTU has proven especially useful in the diagnosis of renal pelvic and 
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urethral cancers 8, 9）, and in detecting bladder cancer 10-12）.  A patient presenting with macroscopic 
hematuria is recommended to undergo CTU in combination with cystoscopy and ultrasonography, 
with a differential diagnosis including urothelial cancer 4, 13）.  However, CTU uses contrast agents, 
meaning patients who suffer from reduced renal function or iodine allergy are precluded, and 
patients are subject to high X-ray exposure.  In conjunction with the development of devices 
like 3T MRI equipment, new imaging modalities such as diffusion-weighted imaging are now 
being used in various domains for detecting cancer and determining its spread, with the major 
advantage that MRI does not involve contrast agents 14, 15）.  To our knowledge, here we present 
the rst direct comparison of CTU and MRI for the detection of bladder cancer.
Methods
　All cases for this study were selected from patients undergoing cystoscopy from Jan 2008 
to Dec 2014 at Showa University Hospital.  Of patients diagnosed with bladder cancer based 
on biopsy or surgery, we selected 58 who had undergone CTU and bladder MRI examina-
tions within one month of each other.  The mean age was 67 years （range : 35-84 years）, with 
46 males and 12 females.  We selected only cases for which a minimum of T2-weighted and 
diffusion-weighted MRI imaging was implemented.  The MRI comprised whole-body 3T MRI 
（MAGNETOM Trio, A Tim System 3T : Siemens, Germany） and whole-body 1.5T MRI （MAG-
NETOM Avanto 1.5T : Siemens, Germany ; MAGNETOM ESSENZA 1.5T : Siemens, Germany ; 
Singa HDxt 1.5T : G.E., USA）, with 3T devices used for 45 cases and 1.5T devices for 13 cases. 
For the 3T MRI devices, T2-weighted images were captured with fast spin-echo imaging under 
settings of TR/TE＝ 4000-4500/82-88 ms and FOV＝ 22 cm ; diffusion-weighted images were 
captured under settings of TR/TE＝ 3300-3800/68-70 ms, B-value＝ 0, 50, 5000, 1000 s/mm, and 
FOV＝ 35-38 cm.  For 1.5T MRI devices, T2-weighted images were captured with fast spin-
echo imaging under settings of TR/TE＝ 4000～ 4500/91～ 99 ms and FOV ＝ 22 cm ; diffusion-
weighted images were captured under settings of TR/TE＝ 3300～ 3800/77～ 84 ms, B-value＝
50, 5000, 1000 s/mm, and FOV＝ 35 cm.
　The CT procedures comprised 64-slice MDCT （SOMATOM Sensation 64 : Siemens, Germany）, 
128-slice MDCT （SOMATOM Definition AS : Siemens, Germany）, and 4-slice MDCT （Light 
Speed Plus : G.E., USA）.  After simple CT from the upper pole of the kidney to the bladder, 
100 ml of non-ionic iodine contrast agent （300 mg/ml） was intravenously injected for CTU : after 
80 seconds, the renal parenchyma phase was imaged from above the diaphragm to the pubis, 
and after 8 minutes, the excretory phase was imaged from the upper pole of the kidney to the 
bladder.  If sufcient contrast was not achieved in the 8-min images, those hematuria patients 
40 years and older were subjected to a second round of imaging, 12 minutes after the initial 
injection, from the upper-pole kidney to the bladder.  Three-dimensional images were constructed 
using excretory phase images, including maximum intensity projection （MIP） and volume render-
ing （VR） images. For simple CT, renal parenchyma phase CT, and excretory phase CT, 5-mm 
axial images were captured; coronal images were also captured for the excretory phase.
　In the evaluation of bladder cancer, up to three lesions per patient were included in analysis 
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for cases of multiple bladder cancer. Two independent evaluators―Reader 1 and Reader 2―
diagnosed the presence of bladder tumors using MRI and CT axial images.  T2-weighted and 
diffusion-weighted images were interpreted and evaluated for MRI, while post-contrast images of 
the renal parenchyma and excretory phases were examined for CTU.  For cases where bladder 
cancer was diagnosed based on histopathological ndings, the diagnosis results for CT and MRI 
images by Reader 1 and Reader 2 were compared with cystoscopic and surgical ndings.  Sta-
tistical analysis by McNemar’s test was conducted using SPSS version 17.0.  P-values of ＜ 0.05 
were considered statistically signicant.  Ethical approval for this retrospective study was granted 
by the institutional review board, and patient consent was not required.
Results
　The observed bladder cancers showed slightly high signals in T2-weighted MRI images and 
high signals in diffusion-weighted MRI images.  In contrast, the, CT images exhibited strongly 
enhanced signals after the administration of contrast agent for 80 cases ; in the excretory phase, 
contrast defects were observed inside bladders lled with contrast agent （Fig. 1-3）.  The maxi-
mum diameter of tumors detectable via CT or MRI was 2.42-67.2 mm （mean : 19.0 mm）; of 
the 73 detectable lesions, 16 were ≥ 30 mm in diameter, 14 were ＞ 20 mm and ≤ 30 mm, 19 
were ＞ 10 mm and ≤ 20 mm, and 24 were ≤ 10 mm.  Detected bladder cancers were classied 
by location according to the publication Cancer Treatment Standards 16）, and comprised 4 apical 
lesions, 3 anterior-wall lesions, 13 posterior-wall lesions, 14 trigonal lesions, 29 left-wall lesions, 14 
right-wall lesions, 11 bladder-neck lesions, 2 prostatic urethral lesions, 1 trigonal–rear-wall–left-wall 
lesion, 1 trigonal–right-wall lesion, and 1 left-trigonal–posterior-wall lesion.  In terms of T-stage, 
there were 53 Ta, 33 T1, 4 T3a, and 1 T4a lesions.
　Using both MRI and CTU for 91 lesions from 58 cases, Reader 1 detected 72 （79.1％） and 
65 cases （71.4％）, respectively, and Reader 2 detected 69 （75.8％） and 70 （76.9％） cases, respec-
tively （Table 1）.  The κ-values for Reader 1 versus Reader 2 were 0.780 for MRI and 0.857 
for CT, showing high diagnostic consistency.  MRI showed a higher lesion detection rate than 
CTU, but this difference was not statistically signicant, with P-values of 0.065 for Reader 1 and 
1.00 for Reader 2.
Discussion
　One of the characteristic features of bladder carcinoma is the multitude of occurrences in 
time and space, thus there is a high frequency of recurrence.  In this study, there were multiple 
lesions in 21 cases ; however, we evaluated only three lesions maximum per bladder because of 
the difculty in evaluating all lesions in those patients with multiple bladder tumors.  Urothelial 
neoplasms of the urinary bladder may be subdivided into papillary （papillomas, low malignant 
potential, and papillary carcinoma） and non-papillary （urothelial carcinoma in situ and invasive） 
categories.  In this study, we did not consider the distinct morphological features of the bladder 
carcinoma with CT or MRI, although further studies should add such a comparison because 
these morphological features can be important in staging of the bladder carcinoma.
Akifumi NIIYA, et al58
　A denitive diagnosis of bladder cancer is generally obtained by rst conrming the lesion 
by cystoscopy or transabdominal ultrasonography, followed by histopathological conrmation of 
tumor tissue excised by a trans-urethral resection of bladder tumor （TURBT） procedure12, 17）. 
Trans-abdominal ultrasonography is a non-invasive, convenient testing method that is useful for 
diagnosing bladder cancer ; however, it can be difcult to evaluate the whole bladder by this 
procedure due to abdominal gas and poor objectivity.  Cystoscopy is the most reliable testing 
method, but it is highly invasive, and not always easy to perform.  Cystoscopy should be done 
when urine cytology is positive, but no bladder tumor is detected on diagnostic imaging, because 
it is not possible to detect at lesions or carcinoma in situ on CT or MRI.  However, it may be 
useful for performing CT or MRI prior to cystoscopy because the result gives the urologist gross 
information of the existence or non-existence of the bladder carcinoma.
　CTU has gained wider use recently as a method for urinary tract screening, and high detec-
tion rates for bladder cancer are visible in past reports 11, 12）.  Among bladder cancer detection 
rates in the literature, 93％ reported by Turney et al 11） is high compared with our rates of 71.4％ 
Fig. 1.  Bladder cancer on the left posterior wall
A :  T2-weighted MR image showing a small tumor in the left posterior wall of the bladder.
 B :  Diffusion-weighted image demonstrating a high signal tumor （arrow）.
 C :  CT image 80 sec after administration of intravenous contrast agent, showing a small, enhanced nodule 
in the posterior wall of the bladder.
D :  Excretory phase CT showing a small filling defect in the opacified urinary bladder.
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（Reader 1） and 76.9％ （Reader 2）, but given that cystoscopy was not performed in our study 
when no abnormality was present on CTU, it is possible that our values include false negatives. 
However, our rates support a study by Sadow et al 12） who reported 79％ detection in comparing 
cystoscopy and CTU ndings for all of their patients.
　MRI offers excellent tissue contrast, and thus permits satisfactory bladder cancer detec-
tion without the use of contrast agents 14）.  In addition, the recently developed diffusion-
weighted imaging is highly useful for tumor detection generally, and in bladder cancer detection 
specically 18, 19）, with reported rates of 98.1％ 18） and 89％ 19）.  Compared with our own results of 
79.1％ （Reader 1） and 75.1％ （Reader 2）, these detection rates are quite high, probably due to 
differences in tumor size among the studies.  Specically, Abou-El-Ghar et al 18） detected a mean 
bladder tumor size of 29 mm and Halefoglu 19） detected a mean size of 36.6 mm, much larger 
than the values in the present study.  This difference seems particularly affected by the large 
number of tumors less than 20 mm in diameter in our cases, for which the mean maximum 
diameter of tumors was 19.0 mm.
Fig. 2.  Bladder cancer in the right posterior wall detected on MRI, but not on CTU
A :  T2-weighted MR image showing a small tumor in the right posterior wall of the bladder （arrow）.
 B :  Diffusion-weighted image demonstrating a high signal tumor （arrow）.
 C :  CT image 80 sec after administration of intravenous contrast agent, showing no tumor in the bladder.
D :  Excretory phase CT showing no small filling defect in the opacified urinary bladder.
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Fig. 3.  Bladder cancer on the right posterior wall only seen on enhanced CT
A :  T2-weighted MR image showing no tumor in the bladder.
 B :  Diffusion-weighted image demonstrating no tumor, however the signal may be due to susceptibility 
artifact from gas in the dilated rectum.
 C :  CT image 80 sec after administration of intravenous contrast agent, showing a small, enhanced nodule 
in the right posterior wall of the bladder （arrow）.
 D : Excretory phase CT showing no definite filling defect in the opacified urinary bladder.
Table 1.  CTU vs. MRI for detection of bladder cancer
Bladder cancer location
Reader 1 Reader 2
n MRI CTU MRI CTU
DM  4  2  1  2  2
AW  3  3  3  3  3
PW 13 11  8 11 10
TG 14 11 10 10 10
lt-LW 29 25 22 24 24
rt-LW 14 11 10 10 12
NK 11  8  8  8  8
others  3  1  1  1  1
91 72 65 69 70
DM : dome     TG : trigone 　　　   NK : neck
AW : anterior wall  lt-LW : left lateral wall
PW : posterior wall rt-LW : right lateral wall
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　In our comparison of CTU （renal parenchyma phase and excretory phase） versus non-
contrast MRI （T2-weighted and diffusion-weighted）, the bladder cancer detection rate by MRI 
was higher for both Reader 1 and Reader 2, but this difference was not statistically signicant. 
Cystoscopy is the gold standard for bladder cancer detection, but it has been reported that this 
invasive test can be omitted, patient condition permitting, by conducting CTU instead 20-22）.  Our 
results suggest that MRI, which requires neither X-ray exposure nor the use of contrast agents, 
possesses an essentially equivalent detection rate to CTU for bladder cancer.  We therefore pro-
pose that MRI, with its even-lower invasiveness than CT, could be a superior screening method 
for bladder cancer.
　This research had the following limitations.  First, we analyzed only cases of bladder cancer 
diagnosed by cystoscopy.  For this reason, the only measure that was compared between screen-
ing methods was detection rate.  However, it is clinically difcult to conduct MRI for all patients 
with suspected bladder cancer based on hematuria, and a prospective study would be necessary 
to compare CTU and MRI with an adequate measure of specificity.  Compared with using 
cystoscopy, our bladder cancer detection rates for CTU and MRI were certainly not high.  Since 
CTU and MRI were limited to three lesions in cases of multiple bladder cancer, the detection 
rates would likely drop even lower if the remaining small tumors were included.  For MRI to 
be highly useful as a screening examination for bladder cancer, further progress in MRI equip-
ment as well as improvements in diagnostic techniques are needed.
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